Study of Aberrant Modifications in Peptides as a Test Bench to Investigate the Immunological Response to Non-Enzymatic Glycation
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
31903893
DOI
10.14712/fb2019065040195
PII: file/5905/fb2019a0020.pdf
Knihovny.cz E-zdroje
- MeSH
- diabetes mellitus 1. typu metabolismus MeSH
- glykosylace MeSH
- glyoxal metabolismus MeSH
- imidazoly metabolismus MeSH
- imunoanalýza MeSH
- ketosy metabolismus MeSH
- lidé MeSH
- lysin chemie metabolismus MeSH
- peptidy chemie metabolismus MeSH
- posttranslační úpravy proteinů MeSH
- produkty pokročilé glykace metabolismus MeSH
- pyruvaldehyd metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- glucosone MeSH Prohlížeč
- glyoxal MeSH
- imidazolone MeSH Prohlížeč
- imidazoly MeSH
- ketosy MeSH
- lysin MeSH
- peptidy MeSH
- produkty pokročilé glykace MeSH
- pyruvaldehyd MeSH
A side effect of diabetes is formation of glycated proteins and, from them, production of advanced early glycation end products that could determine aberrant immune responses at the systemic level. We investigated a relevant aberrant post-translational modification (PTM) in diabetes based on synthetic peptides modified on the lysine side chain residues with 1-deoxyfructopyranosyl moiety as a possible modification related to glycation. The PTM peptides were used as molecular probes for detection of possible specific autoantibodies developed by diabetic patients. The PDC-E2(167-186) sequence from the pyruvate dehydrogenase complex was selected and tested as a candidate peptide for antibody detection. The structure-based designed type I' β-turn CSF114 peptide was also used as a synthetic scaffold. Twenty-seven consecutive type 1 diabetic patients and 29 healthy controls were recruited for the study. In principle, the 'chemical reverse approach', based on the use of patient sera to screen the synthetic modified peptides, leads to the identification of specific probes able to characterize highly specific autoantibodies as disease biomarkers of autoimmune disorders. Quite surprisingly, both peptides modified with the (1-deoxyfructosyl)-lysine did not lead to significant results. Both IgG and IgM differences between the two populations were not significant. These data can be rationalized considering that i) IgGs in diabetic subjects exhibit a high degree of glycation, leading to decreased functionality; ii) IgGs in diabetic subjects exhibit a privileged response vs proteins containing advanced glycation products (e.g., methylglyoxal, glyoxal, glucosone, hydroimidazolone, dihydroxyimidazolidine) and only a minor one with respect to (1-deoxyfructosyl)-lysine.
Diabetology and Dietetics Department of Medicine University of Padova Padova Italy
Istituto di Ricerca Pediatrica Città della Speranza Padova Italy
Citace poskytuje Crossref.org